Table 2.
Baseline demographic and clinical characteristics for all patients
| Variable | NCCTG (n = 469; No. [%]) | NABTC (n = 596; No. [%]) | All (n = 1065; No. [%]) |
|---|---|---|---|
| Patient | |||
| Age (years) median (range) | 52.2 (18.2–81.2) | 49.3 (20.2–84.5) | 50.9 (18.2–84.5) |
| Gender | |||
| Male | 294 (63) | 382 (64) | 676 (64) |
| Female | 175 (37) | 214 (36) | 389 (36) |
| Race/ethnicity | |||
| White | 416 (99) | 556 (93) | 972 (95) |
| Nonwhite | 6 (1) | 40 (7) | 46 (5) |
| Missing | 47 | 0 | 47 |
| Baseline ECOG performance score | |||
| ≤1 | 278 (59) | 565 (95) | 843 (79) |
| ≥2 | 190 (41) | 31 (5) | 221 (21) |
| Missing | 1 | 0 | 1 |
| Year of study entry | |||
| 1980–1989 | 152 (32) | 0 (0) | 152 (14) |
| 1990–1999 | 223 (48) | 188 (32) | 411 (39) |
| 2000–2004 | 94 (20) | 408 (68) | 502 (47) |
| Disease | |||
| Time since initial diagnosis (weeks) Mean (range) | 87 (9–1233) | 95 (10–814) | 91 (9–1233) |
| Initial grade | |||
| II | 35 (8) | 55 (11) | 90 (9) |
| III | 74 (17) | 88 (17) | 162 (17) |
| IV | 339 (76) | 372 (72) | 711 (74) |
| Missing | 21 | 81 | 102 |
| Last known grade | |||
| III | 90 (19) | 159 (27) | 249 (23) |
| IV | 379 (81) | 437 (73) | 816 (77) |
| Last known histology | |||
| Anaplastic astrocytoma | 59 (13) | 101 (17) | 160 (15) |
| Anaplastic oligodendroglioma | 18 (4) | 39 (7) | 57 (5) |
| Anaplastic oligoastrocytoma | 19 (4) | 19 (3) | 38 (4) |
| Glioblastoma multiforme | 341 (74) | 437 (73) | 778 (74) |
| Grade IV oligoastrocytoma | 26 (6) | 0 (0) | 26 (2) |
| Missing | 6 | 0 | 6 |
| Treatment | |||
| Extent of primary resection | |||
| None | 3 (1) | 0 (0) | 3 (0) |
| Biopsy | 86 (20) | 128 (24) | 214 (22) |
| Subtotal resection | 216 (51) | 245 (47) | 461 (48) |
| Gross total resection | 123 (29) | 154 (29) | 277 (29) |
| Missing | 41 | 69 | 110 |
| Baseline steroid use | |||
| Yes | 279 (75) | 326 (55) | 605 (63) |
| No | 92 (25) | 270 (45) | 362 (37) |
| Missing | 98 | 0 | 98 |
| Baseline anticonvulsant use | |||
| Yes | 103 (60) | 461 (77) | 564 (73) |
| No | 70 (40) | 135 (23) | 205 (27) |
| Not defined/unknown | 296 | 0 | 296 |
| Prior chemotherapy | |||
| Yes | 388 (83) | 459 (77) | 847 (80) |
| No | 79 (17) | 136 (23) | 215 (20) |
| Missing | 2 | 1 | 3 |
| Prior nitrosoureas | |||
| Yes | 240 (62) | 220 (37) | 460 (47) |
| No | 149 (38) | 376 (63) | 525 (53) |
| Missing | 80 | 0 | 80 |
| New Factors | |||
| Prior TMZ use | |||
| Yes | NA | 292 (49) | 292 (49) |
| No | NA | 304 (51) | 304 (51) |
| Type of treatment center | |||
| Academic | 131 (28) | 596 (100) | 727 (68) |
| Community | 338 (72) | 0 (0) | 338 (32) |
| Number of prior relapses | |||
| ≤1 | 412 (100) | 475 (90) | 887 (94) |
| ≥2 | 0 (0) | 56 (10) | 56 (6) |
| Missing | 57 | 65 | 122 |
| Initial low-grade histology | |||
| Yes | 35 (8) | 55 (10) | 90 (9) |
| No | 413 (92) | 476 (90) | 889 (91) |
| Missing | 21 | 65 | 86 |
| Current TMZ | |||
| Yes | 0 (0) | 202 (34) | 202 (19) |
| No | 469 (100) | 394 (66) | 863 (81) |
Abbreviations: NABTC, North American Brain Tumor Consortium; NCCTG, North Central Cancer Treatment Group; TMZ, temozolomide.